Why the Probiotec (ASX:PBP) share price is surging 7% today

The company's latest trading update has boosted investor confidence. We take a closer look…

| More on:
green arrow representing a rise in the share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Probiotec Limited (ASX: PBP) share price is on the move during late afternoon trade. This comes after the pharmaceutical products company provided investors with a trading update and earnings guidance for FY21.

At the time of writing, Probiotec shares are up 7.18% to $2.09.

How is Probiotec performing in FY21? 

Investors are snapping up Probiotec shares following the company's trading update and strong earnings outlook.

According to its release, Probiotec announced it is continuing to deliver on its strategy, increasing value for shareholders. Both existing and new customers have inquired about the company's onshore manufacturing capability.

The company stated that its pharmaceutical product categories affected by COVID-19 are beginning to recover. It is anticipated that this will progressively improve throughout the first-half of FY22, with normal levels returning in H2 FY22.

Although, the current lockdown in Victoria is expected to have a slight impact on the overall group's earnings for FY21.

Pleasingly, Probiotec's recent acquisition of Multipack-LJM in January this year has performed in line with expectations for the 6 months. The business' earnings are weighted more towards the second-half end of the year (July to December). With that in mind, the company is focused on using Multipack-LJM's toolkit to attract more customers and drive revenue growth.

Looking ahead, Probiotec is forecasting revenue to be in the range of $118 million to $122 million. This is a minimum increase of 10% on FY20's result of $107 million.

Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) is projected to come between $21 million and $22 million. When compared against the prior corresponding period ($16.9 million in FY20), this is around a 25% jump.

Underlying earnings per share (EPS) is predicted to drop from FY20's result (11.1 cents per share). This metric is assumed to fall somewhere between 10 cents and 11 cents per share.

Probiotec share price snapshot

In November, Probiotec shares raced higher following notice of its planned acquisition of contract packing specialist, Multipack-LJM. The company's share price reached an all-time high of $2.50 when the takeover was completed in January.

Since then, Probiotec shares have been on a downhill trend, posting a loss of 12% on year-to-date share price performance.

Based on today's price, Probiotec has a market capitalisation of roughly $163 million, with 78 million shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Probiotec Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »